Elevated METTL1 expression in tumor cells increases their sensitivity to specific chemotherapeutic drugs that target chromatin histone methylation, as well as the ERK–MAPK and WNT signaling pathways, suggesting METTL1 as a potential biomarker for drug sensitivity. Here, METTL1 is linked to neoplasm.